Technical Science
The science behind aesthetic medical products
Evidence-based technical explanations for medical directors, R&D buyers, and clinical procurement teams — covering HA chemistry, biostimulators, botulinum toxin unit differences, thread science, and injectable categories.
HA Cross-Linking Chemistry
How BDDE chemistry, degree of modification, and rheological properties determine clinical performance.
The chemistry of cross-linking
Hyaluronic acid in its natural state is rapidly degraded by hyaluronidase — the enzyme present throughout skin tissue — with a half-life of hours to days. To produce a durable injectable filler, HA chains must be chemically cross-linked. The industry-standard cross-linker is BDDE (1,4-butanediol diglycidyl ether), which forms covalent ether bonds between HA disaccharide units, creating a three-dimensional hydrogel network.
Degree of Modification (DoM)
DoM measures the percentage of HA repeat units that are bonded to BDDE molecules. A higher DoM creates a denser network: greater resistance to hyaluronidase, longer clinical duration, and higher firmness (G-prime). A lower DoM produces a softer gel with more tissue-like behavior — appropriate for superficial planes where natural movement integration matters. DoM is not standardly disclosed on product labels but can be obtained from technical datasheets.
Elastic modulus G-prime and viscous modulus G-double-prime
G-prime (the storage or elastic modulus) quantifies a gel resistance to deformation. G-double-prime (the loss or viscous modulus) quantifies its ability to flow under stress. In clinical terms: high G-prime = structural support and lift capacity; high G-double-prime = flow and spreadability. Optimal product selection maps G-prime to the mechanical demands of the target anatomical zone.
Cohesivity and tissue integration
Cohesivity describes how well a gel holds together as a unit rather than dispersing into surrounding tissue. A highly cohesive gel maintains shape and position; a less cohesive gel integrates more diffusely with tissue — providing a more natural appearance in dynamic zones. Cohesivity is assessed by the drop test in quality control and is correlated with cross-linking architecture rather than HA concentration alone.
Botulinum Toxin: Units Are Not Equal
Why unit potency differs between brands and the clinical risks of assuming equivalence.
The LD50 unit system
Botulinum toxin potency is measured in units defined by the murine LD50 assay — the dose lethal to 50% of a group of test mice. Each manufacturer runs this assay against their own internal reference standard under proprietary conditions. The result: one unit of onabotulinumtoxinA (Botox) is not the same biological dose as one unit of abobotulinumtoxinA (Dysport) or one unit of letibotulinumtoxinA (Hugel). Clinical dosing tables cannot be shared directly across brands.
Conversion ratios and their uncertainty
Empirically derived conversion ratios between products are clinically documented but carry uncertainty ranges. Common references suggest abobotulinumtoxinA requires approximately 2.5x the unit count of onabotulinumtoxinA for equivalent glabellar effect — but this ratio varies by anatomical site, injection depth, and individual patient pharmacokinetics. Clinicians should treat conversion ratios as starting estimates requiring individual titration.
Procurement implications
For procurement teams sourcing botulinum toxin products: always specify by International Nonproprietary Name (INN) and brand separately, verify the product storage requirements (typically 2-8 deg C) and handling protocol, confirm the product approved indications match your clinical use, and ensure your clinical team is trained on the specific product — not just botulinum toxin generically.
Reconstitution and dilution
Botulinum toxin products are typically supplied as lyophilised powder and must be reconstituted with sterile, preservative-free saline before injection. Dilution volume directly affects clinical spread and onset. Final concentration (units/mL) must be calculated per product and per indication. Errors at the reconstitution step are a common source of under- or over-treatment in clinical practice.
Collagen Biostimulators
PLLA, PCL, and CaHA: mechanism of action, onset timeline, and clinical positioning.
The biostimulation principle
Unlike fillers that act primarily through volumetric replacement, biostimulators trigger the body own collagen synthesis cascade. They deliver a controlled stimulus — usually a biodegradable particle or microsphere — that induces a localised foreign body response. Macrophages and fibroblasts respond by producing new collagen I and III, gradually restoring dermal architecture and volume.
PLLA (Poly-L-Lactic Acid)
PLLA microspheres are supplied as freeze-dried powder, reconstituted with sterile water and lidocaine before injection. Results appear gradually over 2-6 months as new collagen matures. Multiple sessions (typically 3) are required. Duration of effect: 18-24 months. Best indication: diffuse facial volume loss, temple hollowing, body skin laxity. Risk profile includes nodule formation if injected superficially or with inadequate dilution volume.
CaHA (Calcium Hydroxylapatite)
CaHA microspheres in a carboxymethylcellulose carrier provide immediate volumisation plus secondary biostimulation as the carrier absorbs (typically 2-3 months). The remaining CaHA microspheres continue to stimulate fibroplasia for 12-18 months before degrading. Best indication: mid-face, jawline definition, hand rejuvenation, collagen stimulation in skin laxity. CaHA is radiopaque — inform radiologists of prior injection.
PCL (Polycaprolactone)
PCL microspheres in a CMC carrier behave similarly to CaHA at injection but absorb more slowly (18-24 months for the scaffold). Biostimulatory effect is sustained and progressive. PCL products typically require fewer sessions than PLLA. Best indication: global skin quality improvement, subtle volumisation with long biostimulatory duration.
Thread Lift Science
PDO and PCL barbed threads: tissue anchoring mechanism, tensile strength, and absorption timeline.
Mechanism of lift
Barbed or cog threads achieve repositioning through mechanical anchoring: the barbs (directional cuts or moulded projections) engage the subdermal fibrous septae, creating resistance when the thread is tensioned. The immediate lift is mechanical. A secondary biostimulatory effect — fibroblast activation around the thread scaffold — develops over weeks and partially maintains the result as the thread degrades.
PDO (Polydioxanone)
PDO is the same material used in surgical sutures for decades. In the aesthetic context, it is used for barbed lifting threads and smooth mono threads. Absorption timeline: 6-8 months via hydrolytic degradation. The biostimulatory effect persists for up to 12 months. PDO mono threads (non-barbed) are used for skin quality improvement and superficial collagen stimulation rather than lifting.
PCL (Polycaprolactone) threads
PCL absorbs more slowly than PDO — typically 18-24 months. The extended scaffold duration provides a longer biostimulatory window and may produce stronger collagen remodelling. Tensile strength is higher than PDO during the early post-procedure period. PCL threads are particularly suited to cases where sustained collagen stimulation is the primary goal rather than acute mechanical repositioning.
Clinical evidence and limitations
Peer-reviewed evidence supports statistical improvement in mid-face position and FACE-Q satisfaction scores at 12 months. However, absolute effect size is moderate and patient selection (skin thickness, laxity grade, anatomy) strongly influences outcome. Thread lifts are not a replacement for surgical rhytidectomy in patients with advanced laxity.
Skin Booster vs. Dermal Filler
Rheological differences, injection planes, and clinical indications that distinguish the two product categories.
Definitional distinction
A skin booster is an injectable HA preparation at very low concentration (1-3 mg/mL) with no or minimal cross-linking. It is designed to be injected into the intradermal layer (papillary dermis) using a multi-puncture technique, spreading diffusely to restore dermal hydration. A dermal filler is a cross-linked HA gel (18-24 mg/mL) placed in or below the dermis to provide structural support, volume, or contour correction.
Rheological profile comparison
Skin boosters have very low G-prime (near-water viscosity), high tissue integration, and no cohesive structure — they are designed to spread. Dermal fillers have high G-prime, structured cohesivity, and are designed to maintain position and form. Injecting a filler at skin booster depth, or a skin booster at filler depth, produces suboptimal clinical results and increases risk.
Indications: skin boosters
Skin boosters address intrinsic and UV-induced skin aging at the dermal level: loss of hydration, fine surface lines, dull complexion, and superficial texture irregularities. They do not address volume loss or structural laxity. Ideal candidates are patients whose primary complaint is skin quality rather than morphological change.
Indications: dermal fillers
Dermal fillers address morphological changes: nasolabial folds, marionette lines, lip volume, tear trough depression, mid-face volume loss, temporal hollowing, chin and jaw definition, and non-surgical rhinoplasty. Product selection (G-prime value, cohesivity, concentration) must match the indication.
Common Questions
Frequently Asked
- Why do botulinum toxin units differ between brands?
- Unit potency is measured by a mouse lethality assay (LD50) that is performed in-house by each manufacturer using their own reference standard. Because the assay conditions differ between laboratories, one unit from Allergan (onabotulinumtoxinA) is not equivalent to one unit from Ipsen (abobotulinumtoxinA) or Hugel (letibotulinumtoxinA). Clinicians converting between brands must use clinically validated conversion ratios — not a simple 1:1 substitution.
- How long does HA dermal filler last and what determines duration?
- Duration is primarily determined by the cross-linking degree (Degree of Modification / DoM), placement depth, anatomical location, and individual metabolic rate. Superficial placement in high-mobility areas (lips, perioral) degrades faster than deep structural placement (chin, jaw). Clinically documented duration ranges from 6-9 months for soft lip products to 18-24 months for high G-prime structural fillers.
- What is the difference between PLLA and CaHA biostimulators?
- PLLA (Poly-L-Lactic Acid) works by triggering a controlled foreign body response that stimulates fibroblast activity and new collagen synthesis. Results are gradual (appearing over 2-6 months) and require multiple sessions. CaHA (Calcium Hydroxylapatite) provides immediate volumisation through its calcium microspheres, plus a longer-term biostimulatory effect as the carrier gel absorbs. PLLA is better for diffuse volume loss; CaHA is better where immediate correction is also desired.
- What is the clinical evidence basis for PDO thread lifts?
- PDO (Polydioxanone) threads are absorbed within 6-8 months. Clinical evidence supports a dual mechanism: immediate mechanical repositioning via barb anchoring, and a secondary fibroplasia response that maintains lift. Peer-reviewed data show statistically significant improvement in mid-face position at 12 months vs. baseline, though effect size is moderate compared to surgical approaches. PCL threads absorb more slowly (18-24 months) and have a stronger biostimulatory profile.
- What is a skin booster and how does it differ from a filler?
- A skin booster is an injectable HA preparation at very low concentration (1-3 mg/mL) with minimal or no cross-linking, designed for intradermal microinjection to improve skin hydration, elasticity, and surface quality. A dermal filler uses higher HA concentration (18-24 mg/mL) and extensive cross-linking to provide structural support and volume correction. They are not interchangeable and are placed at different tissue depths.
Request for quotation
Request technical documentation
Three fields and you're done. We reply with available specifications, packaging options and the documentation status for your country.